Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioNTech SE's Ending Cash Position for the quarter that ended in Jun. 2026 was R$57,504 Mil.
BioNTech SE's quarterly Ending Cash Position
increased
from Dec. 2025 (R$49,034 Mil) to Mar. 2026 (R$60,091 Mil) but then
declined
from Mar. 2026 (R$60,091 Mil) to Jun. 2026 (R$57,504 Mil).
BioNTech SE's annual Ending Cash Position
increased
from Dec. 2023 (R$62,323 Mil) to Dec. 2024 (R$62,364 Mil) but then
declined
from Dec. 2024 (R$62,364 Mil) to Dec. 2025 (R$49,034 Mil).
The historical data trend for BioNTech SE's Ending Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.
BioNTech SE's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as
What does a Ending Cash Position of R$57,504 Mil mean?
BioNTech SE (BSP:B1NT34) has a Ending Cash Position of R$57,504 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on BioNTech SE and its competitors.
Is BioNTech SE's Ending Cash Position too high?
BioNTech SE's current Ending Cash Position is R$57,504 Mil. Overall, BioNTech SE has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioNTech SE's Ending Cash Position compare to INSM and INCY?
BioNTech SE's Ending Cash Position of R$57,504 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on BioNTech SE and its competitors. BioNTech SE's current Ending Cash Position is R$57,504 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNTech SE stock overvalued right now?
Based on GuruFocus' analysis, BioNTech SE (BSP:B1NT34) is currently considered Fairly Valued. The stock's GF Value™ is R$27.63, compared to a current price of R$29.03 — trading 5.1% above its estimated fair value. The current Ending Cash Position is R$57,504 Mil. BioNTech SE's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For BioNTech SE (BSP:B1NT34), the current Ending Cash Position is R$57,504 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNTech SE (BSP:B1NT34) Overvalued in 2026?
Based on GuruFocus' analysis, BioNTech SE stock appears to be overvalued.
The current stock price of R$29.03 is trading 5.1% above its estimated GF Value™ of R$27.63.
GuruFocus considers BioNTech SE to be Fairly Valued.
Key valuation signals for BSP:B1NT34:
Ending Cash Position: R$57,504 Mil
GF Value™: R$27.63 vs. price of R$29.03 (5.1% above fair value)
No single metric tells the full story. See the BSP:B1NT34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
50GF Score
Get the complete analysis for BSP:B1NT34
Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:B1NT34 has been successfully added to your 
